Acquisition complements Agilent’s separation and mass spectrometry solutions
Agilent Technologies and Seahorse Bioscience have signed a definitive agreement under which Agilent will acquire Seahorse Bioscience, a leader in providing instruments and assay kits to measure cell metabolism and bioenergetics. Agilent is acquiring Seahorse Bioscience for US$235m in cash.
Exploration into cell metabolism is rapidly accelerating as the links between mitochondrial function and disease are increasingly revealed. Seahorse Bioscience’s leading technology enables researchers to better understand cell health, function and signalling, and how the cell may be affected by the introduction of a specific drug, by providing real-time kinetics to unlock essential cellular bioenergetics data.
Scientists use Seahorse’s proprietary XF Technology to research the role of cell metabolism in neurodegeneration, ageing, cancer, cardiovascular disease, cell physiology, toxicology and hepatobiology, immunology, infectious diseases, mitochondrial diseases, model organisms, obesity, diabetes, metabolic disorders, screening and translational medicine.
‘Seahorse Bioscience’s unique technology is the perfect complement to Agilent’s market-leading separations and mass spectrometry solutions, particularly for metabolomics research and disease research,’ said Patrick Kaltenbach, President of Agilent’s Life Sciences and Applied Markets Group. ‘The combination of these two platforms gives scientists a more comprehensive and faster path to researching the most challenging diseases affecting mankind. Seahorse’s team and technology are an ideal fit for Agilent and for our customers, and we look forward to bringing them on board.’
‘We are proud to have enabled the exploration of bioenergetics in living cells by nearly 10,000 scientists worldwide, and to have created a new category of cell-based assay tools,’ said Jay Teich, Chief Executive Officer, Seahorse Bioscience. ‘Joining Agilent will give many more researchers access to Seahorse tools. And when these two technology rich companies combine, we expect to offer a series of new products and applications that will benefit our customers.’